Medigene presents UniTope and TraCR a universal detection system for 3S recombinant TCRs at ASGCT 2024
In This Article:
Planegg/Martinsried, October 17, 2024. Medigene AG (Medigene or the “Company”, FSE: MDG1, Prime Standard), an oncology platform company focused on the research and development of T cell receptor (TCR)-guided therapies for the treatment of cancer, presented a universal detection system for 3S (specific, sensitive, and safe) recombinant TCRs (rTCRs), UniTope & TraCR, at the American Society of Gene & Cell Therapy (ASGCT) to be held October 16-17, 2024 in Philadelphia, PA in the US.
The presented poster “Seamless Integration of a Universal Epitope into Recombinant TCRs for Tagging and Tracking of TCR-T Cells Expressing 3S TCRs” will be made available after the conference on Medigene’s website: https://medigene.com/science/abstracts/
“We incorporate innovative technologies into our End-to-End Platform, including UniTope and TraCR, a universal detection system for any rTCR across multiple modalities. These two tools may ensure precise tracking and verification of recombinant TCRs contributing to safer and more effective dosing strategies in the development and administration of TCR-guided therapies,” said Dolores Schendel, CSO at Medigene. “Following the promising data previously presented at this year’s annual ESMO meeting for UniTope-modified rTCRs targeting NY-ESO-1/LAGE-1a, we are excited to now share our initial in vitro data for UniTope-modified rTCRs mKRAS G12V. The UniTope tag, when directly integrated, ensures that a unique identifier is always expressed in rTCR sequences. This represents a major improvement over existing techniques for detecting rTCRs in TCR-guided therapies. The use of UniTope and TraCR technologies will significantly enhance our ability to streamline quality control processes and generate highly accurate data for establishing the ideal drug dosage leading to significant cost and time reductions throughout development.”
The poster showcased the Company's newly developed universal TCR tagging and tracking technology, UniTope & TraCR. Through bioinformatic analysis of T cell receptor beta variable sequences, a six-amino-acid peptide, UniTope, was identified, that is absent in natural TCR beta chains and exhibits low immunogenicity. Further, the UniTope sequence allowed each rTCR to be tagged, adaptable for multi-parameter flow cytometry and ideal for standardized tracking and enrichment of rTCR-T cells with a design that's easy to implement in complex gene transfer systems. Alongside this, an antibody (TraCR) was also designed to specifically recognize and bind to this unique peptide sequence, enabling precise tracking of the tagged TCRs.